Session: JOINT Session - The Lymphoma Microenvironment and Its Impact on Therapy
Hematology Disease Topics & Pathways:
Research, Lymphomas, Diseases, Therapies, Lymphoid Malignancies
Disclosures: Kenderian: LEAH Labs: Current holder of stock options in a privately-held company, Research Funding; MustangBio: Patents & Royalties; Viracta/Sunesis: Research Funding; Tolero: Research Funding; Lentigen: Research Funding; Morphosys: Research Funding; Humanigen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties: CART cell therapy , Research Funding, Speakers Bureau; Life Engine: Current holder of stock options in a privately-held company; Juno/BMS: Consultancy, Research Funding, Speakers Bureau; Kite/Gilead: Consultancy, Research Funding, Speakers Bureau; Novartis: Consultancy, Patents & Royalties: CART cell therapy , Research Funding, Speakers Bureau; Mettaforge: Patents & Royalties.
See more of: Scientific Program